Liquidia Corporation Announces $100 Million in New Financings
MORRISVILLE, N.C., Jan. 04, 2024 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ:LQDA) (Liquidia or the Company) announced today that the Company has entered into agreements for an additional $100 million in capital between two transactions with funds associated with Patient Square Capital and HealthCare Royalty (HCRx), respectively.
Related news for (LQDA)
- Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
- U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
- Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics
- Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update
- District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia